STOCK TITAN

Firefly Neuroscience (AIFF) mutually ends $1M securities purchase agreement

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Firefly Neuroscience, Inc. has terminated a previously agreed financing deal. The company and an accredited investor mutually ended a securities purchase agreement dated May 6, 2026, under which Firefly had planned to sell up to 666,667 units at $1.50 per unit, for potential gross proceeds of up to $1,000,000. The termination was agreed in writing and became effective on June 25, 2026, under Section 5.3 of the agreement. This update is reported as the termination of a material definitive agreement.

Positive

  • None.

Negative

  • None.
Item 1.02 Termination of a Material Definitive Agreement Business
A significant contract was terminated, which may affect business operations or revenue.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Maximum units under agreement 666,667 units Units Firefly agreed to issue and sell under the May 6, 2026 securities purchase agreement
Unit purchase price $1.50 per unit Agreed purchase price per unit in the terminated securities purchase agreement
Potential gross proceeds $1,000,000 Aggregate gross proceeds Firefly could have received under the now-terminated agreement
Item classification Item 1.02 Termination of a Material Definitive Agreement under Form 8-K
Effective termination date June 25, 2026 Date the securities purchase agreement termination became effective
securities purchase agreement financial
"the Company entered into a securities purchase agreement (the “Purchase Agreement”)"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
accredited investor financial
"the Company entered into a securities purchase agreement ... with an accredited investor"
An accredited investor is an individual or entity that meets certain financial criteria, such as having a high income or significant net worth, allowing them to invest in private or less regulated investment opportunities. This status matters because it grants access to investments that are often riskier or less available to the general public, reflecting a higher level of financial knowledge or resources.
material definitive agreement regulatory
"Item 1.02 Termination of a Material Definitive Agreement."
A material definitive agreement is a legally binding contract that creates major, long‑term obligations or rights for a company, such as loans, asset sales, mergers, or supplier deals. Think of it like a mortgage or lease for a business: it can change future cash flow, risk and control, so investors watch these agreements closely because they can materially affect a company’s value, financial health and stock price.
Emerging Growth Company regulatory
"Emerging Growth Company Item 1.02 Termination of a Material Definitive Agreement."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
aggregate gross proceeds financial
"for aggregate gross proceeds of up to $1,000,000."
Aggregate gross proceeds are the total amount of money a company expects to receive from a securities offering or financing before any fees, expenses or deductions are taken out. For investors, this number shows the scale of new capital entering the business—like the size of a fuel tank refill—and helps gauge how much cash will be available to pay debts, fund growth or dilute existing ownership.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
false 0000803578 0000803578 2026-06-25 2026-06-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 25, 2026

 

FIREFLY NEUROSCIENCE, INC.

 

(Exact name of registrant as specified in its charter)

 

Delaware   001-41092   54-1167364
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

1100 Military Road, Kenmore, NY   14217
(Address of principal executive offices)   (Zip Code)

 

(888) 237-6412

 

(Registrant’s telephone number, including area code)

 

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   AIFF   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. 

Emerging Growth Company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 1.02 Termination of a Material Definitive Agreement.

 

As previously disclosed in the Current Report on Form 8-K filed by Firefly Neuroscience, Inc. (the “Company”) on May 12, 2026, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with an accredited investor (the “Investor”), dated May 6, 2026, pursuant to which the Company agreed to issue and sell to the Investor up to 666,667 units, at a purchase price of $1.50 per Unit, for aggregate gross proceeds of up to $1,000,000.

 

On June 25, 2026, the Company and the Investor mutually agreed in writing to terminate the Purchase Agreement, pursuant to Section 5.3 thereof, with such termination effective as of June 25, 2026.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
104   Cover Page Interactive Data File (embedded with the Inline XBRL document).

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 26, 2026

FIREFLY NEUROSCIENCE, INC.

     
  /s/ Greg Lipschitz
  Name: Greg Lipschitz
  Title: Chief Executive Officer

 

2

 

FAQ

What material agreement did Firefly Neuroscience (AIFF) terminate?

Firefly Neuroscience terminated a securities purchase agreement with an accredited investor. The agreement, dated May 6, 2026, had allowed the company to issue and sell units for potential gross proceeds of up to $1,000,000 before it was mutually ended.

When did Firefly Neuroscience (AIFF) terminate its securities purchase agreement?

The agreement was terminated effective June 25, 2026. Firefly Neuroscience and the accredited investor mutually agreed in writing on that date to end the May 6, 2026 securities purchase agreement under Section 5.3 of the contract.

How much capital could Firefly Neuroscience (AIFF) have raised under the terminated deal?

The agreement allowed potential gross proceeds of up to $1,000,000. Firefly had agreed to issue and sell up to 666,667 units at a purchase price of $1.50 per unit to an accredited investor before the contract was mutually terminated.

What were the terms of the units in Firefly Neuroscience’s (AIFF) canceled financing?

The company agreed to sell up to 666,667 units at $1.50 per unit. This structure provided for aggregate potential gross proceeds of up to $1,000,000 before the securities purchase agreement was mutually terminated on June 25, 2026.

Why is this Firefly Neuroscience (AIFF) disclosure categorized as termination of a material definitive agreement?

The disclosure falls under the termination of a material definitive agreement because it reports the ending of a signed securities purchase agreement that governed a potential $1,000,000 financing, which is treated as a significant contractual arrangement for reporting purposes.

Filing Exhibits & Attachments

3 documents